Grzegorz Wicher peered through the microscope in Oxford, tracing brown-stained microglia cells as they moved with quiet purpose around neurons. These tiny immune cells, long seen as mere janitors of the brain, were doing something no one expected: they were carefully 'nibbling' away clumps of a harmful protein linked to Parkinson’s disease—without harming the neuron itself. This delicate act of cellular precision, discovered by researchers at the University of Oxford, could change how we treat one of the world’s fastest-growing neurological disorders.
Parkinson’s affects more than 10 million people worldwide. It slowly steals movement, balance, and speech as dopamine-producing neurons die off, weighed down by toxic clumps of a misfolded protein called alpha-synuclein. For years, scientists have searched for ways to stop or remove these clumps. Now, this study reveals that the brain may already have its own defense—one that uses microglia not to destroy entire cells, but to surgically remove only the damaged parts.
Using human stem cell models built from induced pluripotent stem cells (iPSCs), the team watched microglia respond when alpha-synuclein aggregates formed inside neurons. Instead of triggering widespread inflammation or engulfing whole cells, these specialized microglia used a process called trogocytosis—literally 'nibbling'—to extract just the toxic portions. The discovery shows that microglia can protect neurons while preserving their structure and function, a far more refined role than previously understood.
This protective behavior was guided by precise signals: P2RY12 helped microglia sense damage, CD22 acted as an inhibitory brake, and the cytokine IL-10 served as a self-regulating off-switch, preventing overactivity. Using single-cell RNA sequencing, the researchers identified a distinct subpopulation of microglia linked to this beneficial cleanup. Even more telling, they found that a protein called GPNMB—previously linked to Parkinson’s through genetic studies but poorly understood—was highly active during the process. GPNMB levels rose in microglia exposed to diseased neurons and were elevated in the substantia nigra of people with early or full Parkinson’s pathology.
"What is striking is the precision of this response," said Dr. Hung-Ju Chueh, the study’s first author. Their findings, published in Science Translational Medicine, suggest that boosting this natural cleanup system—without triggering harmful inflammation—could lead to treatments that slow or even stop Parkinson’s progression. While still early, this work opens a new path: not fighting the brain’s immune system, but helping it do what it already knows how to do—better.